TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25300885

Group type: EXPERIMENTAL
Intervention: Extended self-help program
Number of subjects: 633

Group type: EXPERIMENTAL
Intervention: Brief screening and feedback intervention
Number of subjects: 633

Group type: COMPARATOR
Intervention: Assessment only (control group)
Number of subjects: 633
Study: 22575031

Group type: EXPERIMENTAL
Intervention: New stone occlusion device
Number of subjects: 59

Group type: COMPARATOR
Intervention: NTrap occluder
Number of subjects: 59
Study: 20230501

Group type: EXPERIMENTAL
Intervention: Deceptive group (n=26)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Truthful group (n=14)
Number of subjects: 40
Study: 18388072

Group type: EXPERIMENTAL
Intervention: Flow-mediated dilation (FMD) in COPD patients
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Nitrate-mediated dilation (NMD) in COPD patients
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: FMD correlation with FEV1/VC ratio
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Multiple linear regression model for FMD
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Multiple linear regression model for NMD
Number of subjects: 44
Study: 15467660

Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 100
Study: 11467701

Group type: EXPERIMENTAL
Intervention: Mifepristone 50 mg followed by gemeprost 0.5 mg
Number of subjects: 1224

Group type: EXPERIMENTAL
Intervention: Mifepristone 50 mg followed by gemeprost 1.0 mg
Number of subjects: 1224

Group type: EXPERIMENTAL
Intervention: Mifepristone 200 mg followed by gemeprost 0.5 mg
Number of subjects: 1224

Group type: EXPERIMENTAL
Intervention: Mifepristone 200 mg followed by gemeprost 1.0 mg
Number of subjects: 1224
Study: 9873176

Group type: EXPERIMENTAL
Intervention: Itraconazole (200 mg twice daily)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 7973199

Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 178

Group type: COMPARATOR
Intervention: Triazolam 0.25 mg
Number of subjects: 178
Study: 2638181

Group type: EXPERIMENTAL
Intervention: 0.3% triclosan toothpaste
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.5% triclosan toothpaste
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouthwash (0.2%)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional fluoride/anionic detergent based toothpaste
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triclosan/zinc formulations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Triclosan (0.2%)
Number of subjects: 0
Study: 267005

Group type: EXPERIMENTAL
Intervention: Placebo declared as analgetics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Placebo declared as hyperaesthetics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Placebo with no effect on pain
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Time of day (morning vs evening)
Number of subjects: 0
Study: 31295649

Group type: EXPERIMENTAL
Intervention: Initial assessment of incisional hernia
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes
Number of subjects: 35
Study: 28118272

Group type: EXPERIMENTAL
Intervention: Isometric neck extension exercise for 3 months
Number of subjects: 65

Group type: COMPARATOR
Intervention: Nonsteroidal anti-inflammatory drugs for 10 days (same for both groups)
Number of subjects: 65
Study: 25712298

Group type: EXPERIMENTAL
Intervention: Acetazolamide 250 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 23608246

Group type: EXPERIMENTAL
Intervention: Cabergoline starting on the day of HCG injection
Number of subjects: 206

Group type: COMPARATOR
Intervention: Cabergoline starting on the day of oocyte retrieval
Number of subjects: 206
Study: 21279990

Group type: EXPERIMENTAL
Intervention: R788 (fostamatinib disodium) 100 mg twice daily
Number of subjects: 219

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 219
Study: 18640170

Group type: EXPERIMENTAL
Intervention: HPV 16 and 18 vaccine (3 doses)
Number of subjects: 7466

Group type: COMPARATOR
Intervention: Hepatitis A vaccine (control)
Number of subjects: 7466
Study: 17055909

Group type: EXPERIMENTAL
Intervention: Glass ionomer cement
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Flowable composite resin
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Polycarboxylate cement
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Resin modified glass ionomer cement
Number of subjects: 60

Group type: COMPARATOR
Intervention: No barrier material (group 5)
Number of subjects: 60
Study: 14641395

Group type: EXPERIMENTAL
Intervention: Nurse telephone calls intervention applied for 12 weeks, consisting of education and reinforcement of diet, exercise, medication adjustment recommendations, and self-monitoring of blood glucose levels.
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no nurse telephone calls)
Number of subjects: 36
Study: 11739980

Group type: EXPERIMENTAL
Intervention: rtPA
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control
Number of subjects: 72
Study: 9241127

Group type: EXPERIMENTAL
Intervention: Intermittent etidronate (400 mg per day for 14 days) followed by calcium (500 mg per day for 76 days), given for four cycles
Number of subjects: 141

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study: 7510990

Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3524231

Group type: EXPERIMENTAL
Intervention: mazindol (2 mg daily)
Number of subjects: 2

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 2
Study: 29766770

Group type: EXPERIMENTAL
Intervention: Intravenous alteplase
Number of subjects: 503

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 503
Study: 27083129

Group type: EXPERIMENTAL
Intervention: Mindful decision‐making training (MDT)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Inhibitory control training (ICT)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Both MDT and ICT
Number of subjects: 119

Group type: COMPARATOR
Intervention: Neither (psychoeducation)
Number of subjects: 119
Study: 25402490

Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 150

Group type: COMPARATOR
Intervention: Beta interferons
Number of subjects: 150
Study: 23748117

Group type: EXPERIMENTAL
Intervention: Morphine (0.08 mg/kg)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Naloxone (8 mg)
Number of subjects: 76
Study: 20453504

Group type: EXPERIMENTAL
Intervention: Individual sampling method
Number of subjects: 35

Group type: COMPARATOR
Intervention: Pooled sampling method
Number of subjects: 35
Study: 18771833

Group type: EXPERIMENTAL
Intervention: Group-based microfinance combined with participatory gender and HIV training
Number of subjects: 845

Group type: COMPARATOR
Intervention: Comparison group (not specified in detail)
Number of subjects: 845
Study: 17240933

Group type: EXPERIMENTAL
Intervention: Colgate Total Toothpaste with dental floss
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Colgate Total Toothpaste without dental floss
Number of subjects: 114

Group type: COMPARATOR
Intervention: Sodium fluoride toothpaste with dental floss
Number of subjects: 114
Study: 12678189

Group type: EXPERIMENTAL
Intervention: abciximab
Number of subjects: 60

Group type: COMPARATOR
Intervention: tirofiban
Number of subjects: 60
Study: 10641576

Group type: EXPERIMENTAL
Intervention: Filgrastim
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 8705740

Group type: EXPERIMENTAL
Intervention: Tissue adhesive (cyanoacrylate)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anchor suture
Number of subjects: 0

Group type: COMPARATOR
Intervention: No suture (unsutured group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All groups (suture, tissue adhesive, unsutured)
Number of subjects: 0
Study: 1889143

Group type: EXPERIMENTAL
Intervention: 200 mg pirenzepine
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 100 mg pirenzepine
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 200 mg pirenzepine at night
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 3902672

Group type: EXPERIMENTAL
Intervention: Timolol 20 mg once daily
Number of subjects: 16

Group type: COMPARATOR
Intervention: Timolol 10 mg twice daily
Number of subjects: 16
Study: 29055257

Group type: EXPERIMENTAL
Intervention: Adjunctive brexpiprazole
Number of subjects: 1056

Group type: COMPARATOR
Intervention: Adjunctive placebo
Number of subjects: 1056
Study: 26850264

Group type: EXPERIMENTAL
Intervention: Percutaneous vertebroplasty (PVP)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Facet blocking (FB)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: PVP
Number of subjects: 206

Group type: COMPARATOR
Intervention: FB
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: PVP and FB
Number of subjects: 206
Study: 25245821

Group type: EXPERIMENTAL
Intervention: Paclitaxel and carboplatin with bevacizumab (n=10)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Paclitaxel and carboplatin without bevacizumab (n=11)
Number of subjects: 21
Study: 23207862

Group type: EXPERIMENTAL
Intervention: Active lacebacks (Group 1)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Passive lacebacks (Group 2)
Number of subjects: 23
Study: 20189174

Group type: EXPERIMENTAL
Intervention: Zhibitai (480 mg orally twice daily)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Atorvastatin (10 mg orally once a day)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Both Zhibitai and Atorvastatin
Number of subjects: 169
Study: 18569754

Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 286

Group type: COMPARATOR
Intervention: Behavioral Counseling
Number of subjects: 286
Study: 17379054

Group type: EXPERIMENTAL
Intervention: Exenatide 10-microg BID after initial 5-microg BID for 4 weeks
Number of subjects: 283
Study: 15497510

Group type: EXPERIMENTAL
Intervention: Lispro (n=11)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Regular insulin (n=10)
Number of subjects: 21
Study: 10884452

Group type: EXPERIMENTAL
Intervention: Systemic thrombolysis using alteplase
Number of subjects: 150
Study: 9050118

Group type: EXPERIMENTAL
Intervention: Family interventions
Number of subjects: 97

Group type: COMPARATOR
Intervention: Individual treatment
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: High-EE families with cannabis abuse
Number of subjects: 97
Study: 8313183

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin (360 mg in 5 days and 480 mg in 7 days)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Piperaquine phosphate
Number of subjects: 101
Study: 3539601

Group type: EXPERIMENTAL
Intervention: Ioxaglate
Number of subjects: 100

Group type: COMPARATOR
Intervention: Iohexol
Number of subjects: 100
Study: 31122494

Group type: EXPERIMENTAL
Intervention: Dual therapy with cilostazol (100 mg, twice per day) and aspirin or clopidogrel
Number of subjects: 1884

Group type: COMPARATOR
Intervention: Monotherapy with aspirin (81 or 100 mg, once per day) or clopidogrel (50 or 75 mg, once per day)
Number of subjects: 1884
Study: 28232599

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 821

Group type: COMPARATOR
Intervention: Everolimus
Number of subjects: 821
Study: 25134047

Group type: EXPERIMENTAL
Intervention: Contingency group (n = 35) required to ingest naltrexone under staff observation
Number of subjects: 67

Group type: COMPARATOR
Intervention: Prescription group (n = 32) given a take-home supply of oral naltrexone
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 67
Study: 23782870

Group type: EXPERIMENTAL
Intervention: Usual cessation support plus referral to Slimming World
Number of subjects: 320

Group type: COMPARATOR
Intervention: Usual cessation support alone
Number of subjects: 320
Study: 21716267

Group type: EXPERIMENTAL
Intervention: S-ketamine (0.2 mg/kg) after pretreatment with ticlopidine (250 mg twice daily)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: S-ketamine (0.2 mg/kg) after pretreatment with itraconazole (200 mg once daily)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Ticlopidine and Itraconazole phases
Number of subjects: 11
Study: 16833023

Group type: EXPERIMENTAL
Intervention: 2 mg risperidone tablet
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: CYP2D6*10 allele
Number of subjects: 24
Study: 12768907

Group type: EXPERIMENTAL
Intervention: Propofol/Remifentanil
Number of subjects: 80

Group type: COMPARATOR
Intervention: Propofol/Fentanyl/Alfentanil
Number of subjects: 80
Study: 11048829

Group type: EXPERIMENTAL
Intervention: 5% glucose infusion
Number of subjects: 81

Group type: COMPARATOR
Intervention: No glucose infusion (control)
Number of subjects: 81
Study: 9070546

Group type: EXPERIMENTAL
Intervention: Arbutamine
Number of subjects: 37

Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 37
Study: 8375090

Group type: EXPERIMENTAL
Intervention: Backpropagation neural networks trained on clinical data
Number of subjects: 807

Group type: EXPERIMENTAL
Intervention: Cross-validation monitoring during training
Number of subjects: 807
Study: 3740576

Group type: EXPERIMENTAL
Intervention: Follow-up telephone call by an ED nurse two to three days after discharge
Number of subjects: 297

Group type: COMPARATOR
Intervention: No follow-up telephone call (control group)
Number of subjects: 297
Study: 29283072

Group type: EXPERIMENTAL
Intervention: Leflunomide
Number of subjects: 144

Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 144
Study: 30165765

Group type: COMPARATOR
Intervention: Horizontal table position
Number of subjects: 270

Group type: COMPARATOR
Intervention: 7° head-down table position
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Patient-specific table position based on correction of pelvic adduction
Number of subjects: 270
Study: 26452698

Group type: EXPERIMENTAL
Intervention: Anaesthetic-ECT time interval
Number of subjects: 84
Study: 24930870

Group type: EXPERIMENTAL
Intervention: Nano Silver Fluoride (NSF)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Water (Control)
Number of subjects: 130
Study: 22901346

Group type: COMPARATOR
Intervention: Lu AA21004 10 mg
Number of subjects: 560

Group type: COMPARATOR
Intervention: Lu AA21004 1 mg
Number of subjects: 560

Group type: COMPARATOR
Intervention: Lu AA21004 5 mg
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 560
Study: 20445497

Group type: EXPERIMENTAL
Intervention: Daily oral sodium bicarbonate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo or equimolar sodium chloride
Number of subjects: 0
Study: 18076275

Group type: EXPERIMENTAL
Intervention: Carbohydrate supplementation (C)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Both conditions (C and P)
Number of subjects: 15
Study: 16052276

Group type: EXPERIMENTAL
Intervention: Epoetin alfa 300 IU/kg/day
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Epoetin alfa 300 IU/kg
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Epoetin alfa 150 IU/kg
Number of subjects: 223

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 223
Study: 11756605

Group type: EXPERIMENTAL
Intervention: D-amphetamine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 9715485

Group type: EXPERIMENTAL
Intervention: Topical prednisolone acetate
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 8140111

Group type: EXPERIMENTAL
Intervention: Modern dressing A
Number of subjects: 0

Group type: COMPARATOR
Intervention: Modern dressing B
Number of subjects: 0
Study: 3048953

Group type: EXPERIMENTAL
Intervention: Evening primrose oil (Efamol)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo olive oil
Number of subjects: 24
Study: 29729978

Group type: EXPERIMENTAL
Intervention: Focused individualized diabetic education sessions before Ramadan
Number of subjects: 320

Group type: COMPARATOR
Intervention: Standard diabetic care (Control)
Number of subjects: 320
Study: 27063162

Group type: EXPERIMENTAL
Intervention: Intensive statin therapy (atorvastatin, 80 mg/day, 3 days before till 3 days after intervention)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard therapy (atorvastatin, 20 mg/day)
Number of subjects: 40
Study: 24462183

Group type: EXPERIMENTAL
Intervention: PtCr‐EES (PROMUS Element everolimus‐eluting stent)
Number of subjects: 1530

Group type: COMPARATOR
Intervention: CoCr‐EES (XIENCE V everolimus-eluting stent)
Number of subjects: 1530
Study: 23185751

Group type: EXPERIMENTAL
Intervention: CMM + chemotherapy (189 cases)
Number of subjects: 366

Group type: COMPARATOR
Intervention: Chemotherapy (177 cases)
Number of subjects: 366
Study: 20400920

Group type: EXPERIMENTAL
Intervention: Target-controlled infusion (TCI) of remifentanil (0.8 ng · mL as effect-site target)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Manually controlled infusion of remifentanil (loading dose of 0.75 μg · kg and 0.075 μg · kg · min as maintenance)
Number of subjects: 22
Study: 17715246

Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin (E + P)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statistical methods for trial monitoring
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monitoring board input
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Safety monitoring
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statistical methods in published reports
Number of subjects: 0
Study: 16261287

Group type: EXPERIMENTAL
Intervention: MCC-135 (4.5 mg/kg/48 hours)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MCC-135 (9.0 mg/kg/48 hours)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MCC-135 (4.5 mg/kg/48 hours) and MCC-135 (9.0 mg/kg/48 hours)
Number of subjects: 0
Study: 12239666

Group type: EXPERIMENTAL
Intervention: Collagenase injection therapy (one dose)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Collagenase injection therapy (dose-response study)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Surgical fasciectomy
Number of subjects: 129
Study: 10665619

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT), delivered in 19 individual sessions over 9 months
Number of subjects: 90

Group type: COMPARATOR
Intervention: Befriending control intervention, delivered in 19 individual sessions over 9 months
Number of subjects: 90
Study: 8842506

Group type: EXPERIMENTAL
Intervention: Propafenone 300 mg tid
Number of subjects: 56

Group type: COMPARATOR
Intervention: Disopyramide 250 mg tid
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Propafenone
Number of subjects: 56

Group type: COMPARATOR
Intervention: Disopyramide
Number of subjects: 56
Study: 1300237

Group type: EXPERIMENTAL
Intervention: Seraspenide
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 53
Study: 6508975

Group type: EXPERIMENTAL
Intervention: Activated charcoal 25 g administered 5 min after drug ingestion on an empty stomach
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Activated charcoal 25 g administered 60 min after drug ingestion on an empty stomach
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Activated charcoal 25 g administered 5 min after drug ingestion after a standard meal
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Activated charcoal 25 g administered 60 min after drug ingestion after a standard meal
Number of subjects: 6
Study: 30753449

Group type: EXPERIMENTAL
Intervention: CPR-retraining based on hands-on rolling refreshers during the 2-month program (G-CPR, n = 53)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Standard one-time training (G-Stan, n = 61)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: CPR-retraining (G-CPR)
Number of subjects: 114
Study: 29459791

Group type: EXPERIMENTAL
Intervention: Fat-based enteral nutrition (group A, n=30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Glucose-based enteral nutrition (group B, n=30)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fat-based enteral nutrition (group A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Glucose-based enteral nutrition (group B)
Number of subjects: 60
Study: 26986776

Group type: EXPERIMENTAL
Intervention: Head elevation during videolaryngoscopy with the McGrath device
Number of subjects: 46

Group type: COMPARATOR
Intervention: Flat head position during videolaryngoscopy with the McGrath device
Number of subjects: 46
Study: 25352865

Group type: EXPERIMENTAL
Intervention: 10% IV dextrose infusion by burettes
Number of subjects: 140

Group type: COMPARATOR
Intervention: 10% mini dextrose boluses
Number of subjects: 140
Study: 22408122

Group type: EXPERIMENTAL
Intervention: Glucocorticoid therapy
Number of subjects: 1066
Study: 18690451

Group type: EXPERIMENTAL
Intervention: Computed tomography (CT) densitometry
Number of subjects: 266
Study: 17991050

Group type: EXPERIMENTAL
Intervention: Mentoring by nursing and other college students
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 16024305

Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg once daily for 4-8 weeks
Number of subjects: 560

Group type: COMPARATOR
Intervention: Omeprazole 20 mg once daily for 4-8 weeks
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg once daily
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: Maintenance with rabeprazole 10 mg or 2x10 mg once daily for a maximum of 48 weeks
Number of subjects: 560
Study: 11745525

Group type: EXPERIMENTAL
Intervention: CoStasis surgical hemostat containing bovine thrombin and collagen with the patient's own plasma
Number of subjects: 176

Group type: COMPARATOR
Intervention: Instat collagen sponge
Number of subjects: 176
Study: 9286804

Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metoclopramide
Number of subjects: 0
Study: 9384841

Group type: EXPERIMENTAL
Intervention: Gradual discontinuation of lithium
Number of subjects: 0

Group type: COMPARATOR
Intervention: Abrupt interruption of lithium
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sharp reduction in lithium dose
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other disorders and treatments (neuroleptics in schizophrenia, antidepressants in recurrent depression)
Number of subjects: 0
Study: 3711599

Group type: EXPERIMENTAL
Intervention: High fat breakfast followed by iv injection of 1000 u heparin (high NEFA protocol)
Number of subjects: 10

Group type: COMPARATOR
Intervention: High carbohydrate breakfast (low NEFA protocol)
Number of subjects: 10